
Danielle M. Brander, MD, of Duke University School of Medicine, opens the discussion with Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, on infection as a competing risk in chronic lymphocytic leukemia (CLL).
Danielle M. Brander, MD, of Duke University School of Medicine, and Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, examine infection as a leading competing risk in chronic lymphocytic leukemia (CLL). They review registry data showing nearly half of patients develop a serious infection and infection contributes to almost a third of deaths, the immune defects intrinsic to CLL, and the 6-to-12-month window of vulnerability after fixed-duration therapy ends. They compare infection rates across AMPLIFY (serious or grade 3 or higher infection in 14% with acalabrutinib plus venetoclax vs 25% with the triplet adding obinutuzumab), ELEVATE-TN, and CLL14 (grade 3 or 4 infection in 17.5% vs 15%), and note similar serious infection rates near 30% across BTK inhibitors in ELEVATE-RR and ALPINE. Dr Braunstein favors continuous therapy for unmutated IGHV and TP53-aberrant disease and urges counseling patients that infection is the key risk of chemotherapy-free regimens.

Danielle M. Brander, MD, of Duke University School of Medicine, opens the discussion with Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, on infection as a competing risk in chronic lymphocytic leukemia (CLL).

Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, walks Danielle M. Brander, MD, of Duke University School of Medicine, through the immune defects intrinsic to chronic lymphocytic leukemia (CLL).

Danielle M. Brander, MD, of Duke University School of Medicine, outlines frontline options in chronic lymphocytic leukemia (CLL), continuous Bruton tyrosine kinase (BTK) inhibitors with or without anti-CD20 antibodies versus fixed-duration venetoclax plus obinutuzumab, and asks what immune recovery looks like once fixed-duration therapy ends.

Danielle M. Brander, MD, of Duke University School of Medicine, reviews infection data from the AMPLIFY trial in chronic lymphocytic leukemia (CLL), which randomized patients to chemoimmunotherapy, acalabrutinib plus venetoclax, or acalabrutinib plus venetoclax plus obinutuzumab.

Danielle M. Brander, MD, of Duke University School of Medicine, turns to the ELEVATE-TN trial in chronic lymphocytic leukemia (CLL), which compared continuous acalabrutinib monotherapy with acalabrutinib plus 6 cycles of obinutuzumab.

Danielle M. Brander, MD, of Duke University School of Medicine, summarizes the CLL14 trial in chronic lymphocytic leukemia (CLL), which randomized patients to chlorambucil plus obinutuzumab or fixed-duration venetoclax plus obinutuzumab given for about 12 months.

Danielle M. Brander, MD, of Duke University School of Medicine, notes that long-term CLL14 follow-up in chronic lymphocytic leukemia (CLL) showed a median progression-free survival of about 76 months with venetoclax plus obinutuzumab overall but roughly 64 months in unmutated IGHV disease and 49 to 50 months with TP53 aberrations.

Danielle M. Brander, MD, of Duke University School of Medicine, compares infection rates across covalent Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL).

Danielle M. Brander, MD, of Duke University School of Medicine, asks how much weight to give real-world and comparative effectiveness data on infection risk in chronic lymphocytic leukemia (CLL), noting that trials do not answer every question and that cross-trial comparison should be avoided.

Closing the OncLive News Network discussion, Danielle M. Brander, MD, of Duke University School of Medicine, asks Marc J. Braunstein, MD, PhD, of NYU Grossman Long Island School of Medicine, for the limitations clinicians should keep in mind when weighing infection risk between regimens in chronic lymphocytic leukemia (CLL) and for a single takeaway.